logo
Caretaker injured by elephant at Delhi zoo

Caretaker injured by elephant at Delhi zoo

Hindustan Times2 days ago

An elephant caretaker in the Delhi zoo suffered injuries on Friday after an Indian elephant at the facility attacked him, zoo officials said, adding that the mahout (caretaker) has been admitted to Ram Manohar Lohia Hospital with fractured ribs.
An official said the animal, Hira, was bothered by the mahout's behaviour.
'Indian elephants are docile by nature. Further, Hira is not in musth (a state where reproductive hormones increase in male elephants, leading to aggressive behaviour) either. There are no permanent mahouts and this can be characterised as mismanagement,' the official said.
A video of the incident was shared on social media platform X (formerly Twitter), which showed the elephant chained to a hook on the ground and three men engaging with him from a distance. Later in the video, the elephant gets aggressive and runs towards the men, while two of them flee. Hira then attacks the third man, injuring him.
'The video shows that the mahout was misbehaving, which likely agitated the elephant,' a zoo official said.
Delhi zoo director, Sanjeet Kumar, said, 'The elephant was not in musth. The contractual staff slipped and came in contact with the elephant's trunk . He has been sent to RML hospital for check-up and treatment. He has been working at the facility for six months now.'
Another zoo official, however, said that the elephant might have been in a pre-musth state.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

6 breakfast ideas to avoid bloating
6 breakfast ideas to avoid bloating

India Today

timean hour ago

  • India Today

6 breakfast ideas to avoid bloating

6 breakfast ideas to avoid bloating Bloating is a common issue during summer. Here are a few breakfast ideas to try and reduce that risk of an uneasy gut. Credit: Unsplash It is rich in healthy fats, fibre content that makes it a healthy option for breakfast. It can help with digestion and lower the risk of bloating. Avocado toast It contains soluble fibre, is packed with nutrients and has a low glycemic index as well. It may help in healthy bowel movement lowering risk of bloating. Oatmeal Yoghurt has probiotics, is protein-rich and good for digestion. Add a topping of fruits to make it a healthier scoop in the morning. Credit: Pexels Yoghurt fruit bowl Eggs are a good source of protein and other nutrients. Omelette, scrambled eggs, sunny side up make up for good breakfast options. Eggs This is a common Indian household breakfast option. It is rich in carbohydrates, iron, fibre and is easy to digest. Poha Poha is gluten free, low in calories and may prevent bloating too. It can be a healthy start to the day. It is packed with vitamins, minerals and has enzymes that aid digestion. Bowl of papaya

Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market
Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market

The Print

timean hour ago

  • The Print

Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market

Insulin is a hormone that helps move glucose (sugar) from the bloodstream into cells to stop it from building up in the bloodstream. Patients with type 1 diabetes or advanced type 2 diabetes need to administer insulin, typically multiple times a day, in order to keep their blood sugar in a healthy range. Now, with a number of Indian drugmakers foraying into the insulin market in the country once dominated by multinational drugmakers—Big Pharma, its cost is expected to dip further. New Delhi: Insulin, a lifeline for nearly all patients with type 1 diabetes and nearly 10 percent of those with type 2 diabetes, is available in India at an average cost of Rs 133 per vial—among the cheapest in the world. With the country seeing a near explosion of diabetes, the size of India's insulin market stood at an estimated Rs 4,404 crore in April this year, according to Pharmatrac, a market research company that tracks the Indian drug market. Its April report, the latest, which ThePrint has seen, said, 'Indian players are making a steady entry in the Insulins market that was once dominated by MNCs'. Four Indian companies have launched various insulin brands in India over the last two years in the segment where multinationals such as Novo Nordisk, Eli Lilly and Company and Sanofi have ruled the roost, according to Pharmatrac statistics. It added that with innovator companies like Eli Lilly and Novo Nordisk increasingly focusing on the anti-obesity segment (Mounjaro, Ozempic and Wegovy), it opens 'doors of opportunity for the Indian players' to expand their footprint. According to data from the Pharmatrac report, of over 90 insulin brands available in the Indian market, 14 have a collective market share of more than 80 percent. Of these, 11 are owned by either Novo Nordisk, which has a tie-up with Abbott for marketing them in India, or Sanofi, while one brand, Huminsulin by US-based pharma giant Eli Lilly, was sold to Indian drugmaker Lupin last year. The two best-selling insulin brands in the country include Mixtard and Ryzodeg, both by Danish drugmaker Novo Nordisk. Mixtard alone has a market of over Rs 800 crore in India. The only Indian company, which has two brands among the top-selling 14 insulin brands, is Ahmedabad-based Eris Lifesciences. Indian companies that have entered the segment since 2023 include USV, Anthem Biopharma, Cadila and Mankind. Additionally, Cipla, following a strategic tie-up with Eli Lilly, launched its insulin drug, Lyumjev, in India in October 2023. Pharmatrac statistics also showed that Indian companies, which include Eris Lifesciences, Cipla and Mankind, apart from Lupin, sold insulin worth Rs 1,088 crore between April 2024 and April 2025—24.7 percent of the total insulin market. However, as of now, a large number of diabetics in need of insulin still cannot access or afford the new generation versions that are more convenient to use, and most new brands being launched in India have yet to address this issue. Also Read: Fat-busting drug Mounjaro launched in India. Here's how much it will cost Further price crashes expected In 2023, the Indian Council of Medical Research (ICMR) and Madras Diabetes Research Foundation estimated that nearly 101 million people in India had diabetes. It is suggested that while the majority with the condition have type 2 diabetes, the number of those with type 1 is also estimated to be around 9 lakh, and this includes a large number of those under 18 years of age. Type 1 diabetes, say experts, is characterised by complete loss of the insulin-producing beta cells due to an autoimmune disease or idiopathic (unknown) reasons. Type 2 diabetes, also called diabetes mellitus, on the other hand, is mainly triggered by insulin resistance or the body's inability to respond to insulin, often combined with relatively reduced insulin secretion and is linked with lifestyle issues such as poor dietary habits and lack of physical activity. Nearly 10 percent of patients with type 2 diabetes, mainly those in the advanced or severe stage of the condition, require insulin, but for all patients with type 1 diabetes, insulin is mandatory, mostly 3-4 times a day Type 1 diabetes is growing at a rate of 6.7 percent annually in India, compared to 4.4 percent for type 2 diabetes, the latest Pharmatrac report noted. Diabetologist and researcher Dr V. Mohan underlined that the exact reason why the number of people with type 1 diabetes is growing may not be properly understood, but it could also be due to better awareness about the condition and quicker diagnosis. 'Earlier, many with type 1 diabetes used to die within years of disease onset as they did not get insulin on time, but now they are living longer, and those with type 2 diabetes, after living with the condition for years, typically need insulin,' he said. This is why, the clinician-researcher said, the insulin segment is growing rapidly in the country. Adding, 'More competition is always good because that will help to keep up the quality of the product and also bring down the price of the insulin.' Industry insiders said the trend of Indian firms entering the segment was mainly prompted by expiration of patents on key insulin analogues and rapid global adoption of GLP-1 analogues like semaglutide and tirzepatide, used for diabetes and obesity management 'With diabetes now recognised as a national health priority, domestic companies are investing in biosimilar innovation, scaling production capabilities, and forming strategic collaborations to secure insulin supply for the domestic market,' said Saransh Chaudhary, president (global critical care) of research-driven pharma company Venus Remedies. Innovative therapy, devices for diabetics Till the 70s the insulin used by those in need was derived from animals like pigs and cows, while the 80s saw the advent of human insulin, a type of synthetic insulin made in a laboratory that mimics the insulin our body makes. Over the last 15-20 years, insulin analogues, which are more convenient and quicker to act, have been in use in developed countries. This type of medicine is made in the same way as human insulin but is genetically altered to change the way it acts in the body. More expensive than human insulin, insulin analogues have a different chemical structure and are designed to act more rapidly, within 5-10 minutes of administration and for a longer time of up to 40 hours, ensuring ease in diabetes care. These often come in specifically designed devices such as pre-filled pens that are simply administered through a click, instead of most human insulins in vials that have to be administered as an injection. However, as these formulations are not part of the National List of Essential Medicines (NLEM) and are costlier—typically costing Rs 10,000-15,000 per month—most Indian diabetics in need of insulin therapy cannot afford them. As of now, only some basic formulations of insulin are on the NLEM, whose upper price ceilings are fixed by the government. Once protected by patent, as some of them are now off-patent, their biosimilar versions—just like generics in case of small molecule drugs—have now hit the Indian market, and it could change the affordability issue, underlined Dr Manisha Arora, director, internal Medicine at the CK Birla Hospital. 'The entry of multiple pharmaceutical companies into this space reflects the segment's growth potential and the opportunity to enhance treatment outcomes through competitive pricing and technological advancements,' she said. Increased competition could spur further innovation, improve patient-centric delivery systems, and contribute to a more sustainable and equitable diabetes care ecosystem, Arora added. (Edited by Sanya Mathur) Also Read: ICMR-led consortium seeks health tax on fat, sugar & salt-rich foods to cut adolescent obesity burden

Ultimate guide to whole grain breakfasts for hot weather: 5 cereal-based summer recipes you'll want on repeat
Ultimate guide to whole grain breakfasts for hot weather: 5 cereal-based summer recipes you'll want on repeat

Hindustan Times

time2 hours ago

  • Hindustan Times

Ultimate guide to whole grain breakfasts for hot weather: 5 cereal-based summer recipes you'll want on repeat

Summer is a beautiful paradox — it invites us to slow down, even as it tests our stamina. Our digestive systems become more sensitive, hydration becomes non-negotiable and the desire for light, nourishing meals grows stronger. This is where whole cereals step up as quiet heroes. In an interview with HT Lifestyle, Varsha Gorey, Senior Clinical Dietitian at Apollo Hospitals in Navi Mumbai, explained, 'When the mercury soars and your appetite vanishes, your body still craves nourishment—just in a cooler, calmer form. That's where cereals step in, not as your usual hot porridge or upma, but as the foundation for light, clever meals that refresh while they refuel. Think oats, millets, barley, ragi—everyday Indian grains made deliciously summer-friendly.' According to her, here are some unexpected, nutrition-forward ways to let these cereals shine — without turning up the heat too much. Cook pearl barley till tender, chill, and mix with chopped cucumber, mint, onion, tomato, lemon juice, and a dash of olive oil. Spoon into lettuce leaves for bite-sized salad cups. Make a smooth ragi porridge with milk and dates, cool it down, and pour into popsicle moulds with banana slices. Freeze overnight. Blend soaked cooked jowar with chilled coconut water, raw mango pulp, mint and black salt. Strain slightly and serve over ice. Mix roasted oats with hung curd, grated carrot, salt, and coriander. Spread on multigrain bread and refrigerate. Cut into triangles and serve cold. Swap cracked wheat with little millet. Toss with parsley, lemon juice, tomato, olive oil, and a pinch of jeera. Serve chilled. In a season where simplicity is a form of self-care, these recipes prove that cereals are more than your winter staples. With a little creativity, they become your kitchen's best-kept summer secret—cool, comforting, and quietly powerful. Let your grains breathe this summer. They might just become your favourite thing on the plate. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store